Photosensitization Study in Androgenetic Alopecia
A Within-subject, Randomized, Evaluator-blinded, Vehicle-controlled Study to Assess the Photosensitization Potential of Finasteride Cutaneous Solution(P-3074) in Human Subjects
In the register
The register attaches this trial to Topical finasteride (Almirall), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1
- Sponsor
- Polichem S.A.
- Participants (registry)
- 58
- Start
- May 2016
- Primary completion
- June 2016
- Study completion
- June 2016
- Last registry update
- May 2017
- Countries
- United Kingdom
Conditions studied: Androgenetic Alopecia
Interventions: Finasteride 0.25%, P-3074, Placebo for Finasteride 0.25%, vehicle cutaneous solution, Negative Control, 0.9% aqueous NaCl
Other trials of Topical finasteride
Various Procedural Treatment Options for Androgenetic Alopecia
A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.